Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-17
2007-04-17
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S014800, C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
10410998
ABSTRACT:
Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447860 (1995-09-01), Ziegler
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5521073 (1996-05-01), Davis et al.
patent: 5643755 (1997-07-01), Davis et al.
patent: 5650490 (1997-07-01), Davis et al.
patent: 5814464 (1998-09-01), Davis et al.
patent: 5854202 (1998-12-01), Dedhar
patent: 5879672 (1999-03-01), Davis et al.
patent: 5955291 (1999-09-01), Alitalo et al.
patent: 5972338 (1999-10-01), Godowski et al.
patent: 6030831 (2000-02-01), Godowski et al.
patent: 6166185 (2000-12-01), Davis et al.
patent: 6291646 (2001-09-01), Sledziewski et al.
patent: 6323323 (2001-11-01), Sledziewski et al.
patent: 6455035 (2002-09-01), Suri et al.
patent: 2003/0229023 (2003-12-01), Oliner et al.
patent: 2003/0236193 (2003-12-01), Oliner et al.
patent: WO 95/13387 (1995-05-01), None
patent: WO 95/21866 (1995-08-01), None
patent: WO 96/31598 (1996-10-01), None
patent: WO 98/05779 (1998-02-01), None
patent: WO 199933865 (1999-07-01), None
patent: WO 99/43801 (1999-09-01), None
patent: WO 00/06195 (2000-02-01), None
patent: WO 200023082 (2000-04-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 00/57901 (2000-10-01), None
patent: WO 00/77037 (2000-12-01), None
patent: WO 0075323 (2000-12-01), None
patent: WO 01/62891 (2001-08-01), None
patent: WO 01/71042 (2001-09-01), None
patent: WO 2003030833 (2003-04-01), None
patent: WO 2003057134 (2003-07-01), None
Connell et al. (2001),Ashley Publications Ltd. ISSN 1354-3776, pp. 1171-1203.
Siemeister, et al. “Two independent mechanisms essential for tumor angiogensis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the tie-2 pathway” Cancer Res. 59(13):3185-3191 (Jul. 1, 1999).
Lin Pengnian et al. “Inhibition of tumor angiogensis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth” J. Clin. Invest. 100(8):2072-2078 (1997).
Chao et al. (2000), Genomic Sequence forArabidopsis thalianaBAC F1K23 from Chromosome I. Acc. No. Q9SHQe, EMBL/GenBank/DDBJ database, EMBL; AC007508, AAF 24543, Accessed Dec. 10, 2003.
Syed et al. (2001), “The Effects of Angiopoietin-1 and -2 on Tumor Growth and Angiogenesis in Human Colon Cancer,”Cancer Research61:1255-1259.
Coxon et al. (2002), “Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis,”Arthritis Rheum. 46:2604-2612.
Feige et al. (2000), “Anti-interleukin-1 and anti-tumor necrosis factor-α synergistically inhibit adjuvant arthritis in Lewis rats,”Cell Mol. Life Sci. 57:1457-1470.
Peacock et al. (1992), “Angiogenesis inhibition suppresses collagen arthritis,”J. Exp. Med. 175:1135-1138.
Peacock et al. (1995), “A novel angiogenesis inhibitor suppresses rat adjuvant arthritis,”Cell Immunol. 160:178-184.
Walsh et al. (2001), “Angiogenesis in the pathogenesis of inflammatory joint and lung diseases,”Arthritis Res. 3:147-153.
Carmeliet et al. (2000), “Angiogenesis in cancer and other diseases,”Nature407(6801):249-57.
Putaporntip et al. “Diversity in the Thrombospondin-related Adhesive Protein Gene” Gene 268, 97-104 (2001).
Oliner, Jonathan, et al. “Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2” Cancer Cell 6(5) 507-516 (2004).
Min Hosung
Oliner Jonathan Daniel
Amgen Inc.
Gupta Anish
Marshall & Gerstein & Borun LLP
LandOfFree
Methods of treatment using specific binding agents of human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using specific binding agents of human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using specific binding agents of human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3736709